JGB1741

JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC50 of ～15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC50>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research[1].

Product Specifications

CAS Number

[1256375-38-8]

Product Name Alternative

ILS-JGB-1741

UNSPSC

12352005

Target

Apoptosis; Sirtuin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jgb1741.html

Purity

99.37

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

OC1=C(C2=C(C=C1)C=CC=C2)/C=N/C3=C(C4=C(S3)CCCC4)C(NCC5=CC=CC=C5)=O

Molecular Formula

C27H24N2O2S

Molecular Weight

440.56

References & Citations

[1]Arunasree M Kalle, et al. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun. 2010 Oct 8;401 (1) :13-9.